Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Johannsdottir, Hrefna KJohannesdottir, Gudrun
Agnarsson, Bjarni A
Eerola, Hannaleena
Arason, Adalgeir
Johannsson, Oskar T H
Heikkilä, Päivi
Egilsson, Valgardur
Olsson, Hakan
Borg, Ake
Nevanlinna, Heli
Barkardottir, Rosa B
Issue Date
2004-10-01
Metadata
Show full item recordCitation
Anticancer Res. 2004, 24(5A):2681-7Abstract
BACKGROUND: Chromosomal aberrations in breast tumors from BRCA1 and BRCA2 germ-line mutation carriers are considerably more frequent than what is seen in sporadic breast tumors. According to Comparative Genomic Hybridisation analysis (CGH), deletions on chromosome 4 are one of the most frequent events in BRCA1-associated tumors, suggesting inactivation of specific tumor suppressor genes. MATERIALS AND METHODS: In the present study, 16 microsatellite markers covering chromosome 4 were used to map loss of heterozygosity (LOH) in tumors from BRCA1 (n=41) as well as in tumors from BRCA2 (n=66) mutation carriers and in tumors from unselected cases of breast cancer (n =68). RESULTS: The frequency of LOH in these groups ranged from 16-73% in BRCA1-associated tumors, 13-42% in BRCA2-associated tumors and 8-33% in unselected tumors. LOH was significantly more frequent in BRCA1-associated tumors as compared to BRCA2-associated tumors and unselected tumors, and particularly high (over 70%) at 4q35.2. Pathological variables that were found significantly associated (p< or =0.05) with LOH at specific markers were: high percentage of cells in S-phase, negative estrogen receptor status, young age at diagnosis and large tumors. Deletion mapping indicates the existence of seven non-overlapping regions at chromosome 4, which were identified in all three groups of tumors. Three of these seven regions, 4p16.3-p16.1, 4q27-q32.1 and 4q35.1-4qter, have not been reported in breast cancer previously. CONCLUSION: The results manifest the frequent alterations of chromosome 4 in BRCA1-associated breast tumors and indicate the location of several genes of potential importance in breast cancer development.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldCollections
Related articles
- Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
- Authors: Johannsdottir HK, Jonsson G, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, Heikkila P, Egilsson V, Olsson H, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB
- Issue date: 2006 Sep 1
- Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
- Authors: Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer., Australian Ovarian Cancer Study Management Group.
- Issue date: 2008 Nov 5
- Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
- Authors: Janatova M, Zikan M, Dundr P, Matous B, Pohlreich P
- Issue date: 2005 Mar
- Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
- Authors: van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FB, van't Veer LJ, Nederlof PM
- Issue date: 2005 Feb 1
- Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
- Authors: Jönsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR, Greshock JD, Luts L, Olsson H, Rahman N, Stratton M, Ringnér M, Borg A, Weber BL
- Issue date: 2005 Sep 1